Arcturus Therapeutics Holdings Inc.
ARCT
$12.44
-$0.20-1.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 29.06% | -45.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.06% | -45.37% | |||
| Cost of Revenue | -20.30% | 11.87% | |||
| Gross Profit | 73.77% | -927.65% | |||
| SG&A Expenses | -8.60% | -6.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.72% | 7.16% | |||
| Operating Income | 49.61% | -211.02% | |||
| Income Before Tax | 53.09% | -321.47% | |||
| Income Tax Expenses | -- | 98.16% | |||
| Earnings from Continuing Operations | 53.09% | -334.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.09% | -334.67% | |||
| EBIT | 49.61% | -211.02% | |||
| EBITDA | 50.81% | -231.55% | |||
| EPS Basic | 53.27% | -335.63% | |||
| Normalized Basic EPS | 53.29% | -322.57% | |||
| EPS Diluted | 53.36% | -336.50% | |||
| Normalized Diluted EPS | 53.29% | -322.57% | |||
| Average Basic Shares Outstanding | 0.40% | -0.23% | |||
| Average Diluted Shares Outstanding | 0.40% | -0.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||